Ignite Creation Date:
2024-05-06 @ 2:59 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04485663
Status:
TERMINATED
Last Update Posted:
2022-03-15
First Post:
2020-07-09
Brief Title:
A Study of ALG-010133 Drug to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
Sponsor:
Aligos Therapeutics
Organization:
Aligos Therapeutics
Study Overview
Official Title:
A Phase 1 Double-blind Randomized Placebo-controlled First-in-human Study of Subcutaneously Administered ALG-010133 to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics After Single Ascending Doses Part 1 and Multiple Ascending Doses in Healthy Volunteers Part 2 and Multiple Doses in Subjects With Chronic Hepatitis B Part 3
Status:
TERMINATED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of antiviral activity at the projected efficacious dose
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Randomized Study of ALG-010133 Drug to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None